The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

The sale represents nearly 7.7% of Haleon's issued share capital. Haleon was formed in 2019 through a merger of the consumer healthcare businesses of GlaxoSmithKline (GSK) and Pfizer. Haleon was ...

Pfizer Inc. (NYSE:PFE) has announced the sale of shares worth £2.50 billion ($3.05 billion) in British consumer healthcare giant Haleon, reducing its ownership stake to 7.3% from 15%. The transaction ...

According to J.P. Morgan, Pfizer is expected to sell approximately 700 million ordinary shares, thus lowering its stake from 15% to 7.3%, following Haleon's creation through a merger with GSK in 2019.

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core pharmaceutical operations.

The sale represents nearly 7.7% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British ...

It was formed through the integration of Novartis’ consumer healthcare portfolio in 2015 and Pfizer’s in 2019. It was spun out of GSK, then called GlaxoSmithKline, in a blockbuster 2022 listing.

Pfizer PFE-2.36%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN 1.12%increase; green up pointing triangle for 2.50 billion ...

Haleon was formed in 2019 as a joint venture of Pfizer and GSK PLC's consumer health businesses. It was listed on the London Main Market in July 2022, with Pfizer retaining a 32% stake that it has ...